(+)-Myristinin A, a naturally occurring DNA polymerase β inhibitor and potent DNA-damaging agent

Journal of the American Chemical Society

Volumn 127, Issue 12, 2005, Pages 4140-4141

  Maloney, David J ^a   Deng, Jing Zhen ^a   Starck, Shelley R ^a   Gao, Zhijie ^a   Hecht, Sidney M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED DNA POLYMERASE BETA; DNA DIRECTED DNA POLYMERASE BETA INHIBITOR; ENZYME INHIBITOR; FLAVONOID; MYRISTININ A; MYRISTININ B; MYRISTININ C; PLASMID DNA; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DNA CLEAVAGE; DNA DAMAGE; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; KNEMA ELEGANS; MEDICINAL PLANT; MYRISTICA CINNAMOMEA; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ANALYSIS;

DNA DAMAGE; DNA POLYMERASE BETA; DNA, SUPERHELICAL; ENZYME INHIBITORS; FLAVONOIDS; MYRISTICACEAE; STEREOISOMERISM;

EID: 16244387916     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja042727j     Document Type: Article

References (45)

1. Hecht, S. M. Pharm. Biol. 2003, 41, S68 and references therein.
2. Starck, S. R.; Deng, J.-K.; Hecht, S. M. Biochemistry 2000, 39, 2413.
3. (a) Erasto, P.; Bojase-Moleta, G.; Majinda, R. T. Phytochemistry 2004, 65, 875.
4. (b) Martini, N. D.; Katerere, D. R. P.; Eloff, J. N. J. Ethnopharm. 2004, 93, 207.
5. (c) Khan, M. S. Y.; Hasan, S. M. Indian J. Chem., Sect. B 2003, 42, 1970.
6. (d) Tang, S.; Bremner, P.; Kortenkamp, A.; Schlage, C.; Gray, A. I.; Gibbons, S.; Heinrich, M. Planta Med. 2003, 69, 247.
7. (a) Dumontet, V.; Van Hung, N.; Adeline, M. T.; Riche, C.; Chiaroni, A.; Sevenet, T.; Gueritte, F. J. Nat. Prod. 2004, 67, 858.
8. (b) Kobayakawa, J.; Sato-Nishimori, F.; Moriyasu, M.; Matsukawa, Y. Cancer Lett. 2004, 208, 59.
9. (c) Sonoda, M.; Nishiyama, T.; Matsukawa, Y.; Moriyasu, M. J. Ethnopharm. 2004, 91, 65.
10. (d) Fu, Y.; Hsieh, T.; Guo, J.; Kunicki, J.; Lee, M. Y.; Darzynkiewicz, Z.; Wu, J. M. Biochem. Biophys. Res. Commun. 2004, 322, 263.
11. (e) Hsu, Y. L.; Kuo, P. L.; Liu, C. F.; Lin, C. C. Cancer Lett. 2004, 212, 53.
12. (f) Takahashi, T.; Takasuka, N.; Ligo, M.; Baba, M.; Nishino, H.; Tsuda, H.; Okuyama, T. Cancer Sci. 2004, 95, 448.
13. (a) Lee, J. S.; Kim, H. J.; Lee, Y. S. Planta Med. 2003, 69, 859.
14. (b) Jassim, S. A.; Naji, M. A. J. Appl. Microbiol. 2003, 95, 412.
15. (c) Chiang, L. C.; Chiang, W.; Liu, M. C.; Lin, C. C. J. Antimicrob. Chemother. 2003, 52, 194.
16. (d) Li, Y. L.; Ma, S. C.; Yang, Y. T.; Ye, S. M.; But, P. H. J. Ethnopharm. 2002, 79, 365.
17. (e) Zembower, D. E.; Lin, Y. M.; Flavin, M. T.; Fa-Ching, C.; Korba, B. E. Antiviral Res. 1998, 39, 81.
18. Sawadjoon, S.; Kittakoop, P.; Kirtikara, K.; Vichai, V.; Tanticharoen, M.; Thebtaranonth, Y. J. Org. Chem. 2002, 67, 5470.
19. Compound 1 was also isolated from Horsfieldia amygdaline; see: Katuhiko, H.; Akio, K.; Hirokazu, Y.; Akira, M.; Akira, I.; Akinori, S.; Shengji, P.; Yanhui, L.; Chun, W. Patent WO 9208712, 1992.
20. (a) Chang, Y. C.; Kuo, S. C.; Lin, Y. L.; Wang, J. P.; Huang, L. J. Bioorg. Med. Chem. Lett. 2001, 11, 1971.
21. (b) Kurosawa, W.; Kan, T.; Fukuyama, T. J. Am. Chem. Soc. 2003, 125, 8112.
22. (c) Le Stang, S.; Meier, R.; Rocaboy, C.; Gladysz, J. A. J. Flourine Chem. 2003, 119, 141.
23. (d) Vanden Eynde, J. J.; Mailleux, I. Synth. Commun. 2001, 31, 1.
24. (e) Ruenitz, P. C.; Arrendale, R. F.; Schmidt, W. F.; Thompson, C. B.; Nanavati, N. J. Med. Chem. 1989, 32, 192.
25. (f) Wu, G.; Geib, S. J.; Rheingold, A. L.; Heck, R. F. J. Org. Chem. 1988, 53, 3238.
26. (a) Hatayama, K.; Yokomori, S.; Kawashima, Y.; Saziki, R.; Kyogoku, K. Chem. Pharm. Bull. 1985, 33, 1327.
27. (b) Jung, S. H.; Cho, S. H.; The, H. D.; Lee, J. F.; Ju, J. H.; Kim, M. K.; Lee, S. H.; Ryu, J. C.; Kim, Y. Eur. J. Med. Chem. 2003, 38, 537.
28. (c) Tunoori, A. R.; Dutta, D.; Georg, G. I. Tetrahedon Lett. 1998, 39, 8751.
29. (d) Dewick, P. M. Synth. Commun. 1981, 11, 853.
30. (a) Claisen, L.; Claparède, A. Chem. Ber. 1881, 14, 2460.
31. (b) Schmidt, J. G. Chem. Ber. 1881, 14, 1459.
32. Minami, N.; Kijima, S. Chem. Pharm. Bull. 1979, 27, 1490.
33. Sharpless, K. B.; Amberg, W.; Beller, M.; Chen, H.; Hartung, J.; Kawanami, Y.; Lübben, D.; Manoury, E.; Ogino, Y.; Shibata, T.; Ukita, T. J. Org. Chem. 1991, 56, 4585.
34. This established the absolute stereochemistry at the position corresponding to C-2 in myristinin A and that of (+)-myristinin A as 2S,4R. The assignment was supported by the CD spectrum of the alcohol precursor of 7 (van Rensburg, H.; Steynberg, P. J.; Burger, J. F. W.; van Heerden, P. S.; Ferreira, D. J. Chem. Res., Synop. 1999, 450).
35. Li, L.; Chan, T. H. Org. Lett. 2001, 3, 739.
36. (a) Dess, D. B.; Martin, J. C. J. Org. Chem. 1983, 48, 4155.
37. (b) Dess, D. B.; Martin, J. C. J. Am. Chem. Soc. 1991, 113, 7277.
38. Tückmantel, W.; Kozikowski, A. P.; Romanczyk, L. J., Jr. J. Am. Chem. Soc. 1999, 121, 12073.
39. Saito, A.; Nakajima, N.; Tanaka, A.; Ubukata, M. Tetrahedron 2002, 58, 7829.
40. Kozikowski, A. P.; Tückmantel, W.; Hu, Y. J. Org. Chem. 2001, 66, 1287.
41. Synthesized in three steps from phloroglucinol; see Supporting Information.
42. Robins, M. J.; Wilson, J. S.; Hansske, F. J. Am. Chem. Soc. 1983, 105, 4059.
43. D +60.6 (c 0.13, MeOH)) were comparable.
44. BLM alone (2.5 μM) produced 3.1% growth inhibition, whereas 27 μM 1 produced 1.8%. In combination 22.2% growth inhibition occurred.
45. Canitrot, Y.; Cazaux, C.; Frèchet, M.; Bouayadi, K.; Lesca, C.; Salles, B.; Hoffmann, J.-S. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12586.